

NHSEED - - Economic Study or Review

## **Testing the effects of combining azithromycin with inhaled tobramycin for *P. aeruginosa* in cystic fibrosis: a randomised, controlled clinical trial.**

**Code:** PM34706982

**Year:** 2021 **Date:** 2009

**Author:** Nichols DP

### **Participants**

n=326 from 7 CF centres

### **Interventions**

outpatient treatment for CF patients

### **Outcome measures**

assess and evaluate resources use in outpatient treatment of CF in Germany and compare it with current reimbursement

### **Main results**

Mean costs of 488 Euros per patient (n = 326) and quarter occurred. Remuneration (252 Euros per patient/quarter) covered only 52% of the total costs. Furthermore, a considerable time and financial burden for patients as well as decreasing quality of life with increasing age were found. Costs for medication came to 21,604 Euros per patient/year

### **Authors' conclusions**

Human resources in German CF centers today already are below the requirements set by the European consensus for standards of CF care. It will be crucial in assuring a high level of patient care to reach a cost-covering reimbursement scheme in Germany -

<http://dx.doi.org/10.1136/thoraxjnl-2021-217782>

### **See also**

Thorax. 2021 Oct 27;thoraxjnl-2021-217782. doi: 10.1136/thoraxjnl-2021-217782.

### **Keywords**

Adolescent; Adult; Ambulatory; Child; Infant;